EPISODE · Apr 4, 2019 · 59 MIN
1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson
from Plenary Session - inactive due to federal service · host Plenary Session
In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X Rivaroxaban: doi.org/10.1056/NEJMoa1814630 Apixaban: doi.org/10.1056/NEJMoa1814468 Back us on Patreon! www.patreon.com/plenarysession
What this episode covers
In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X Rivaroxaban: doi.org/10.1056/NEJMoa1814630 Apixaban: doi.org/10.1056/NEJMoa1814468 Back us on Patreon! www.patreon.com/plenarysession
NOW PLAYING
1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.